[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gout-initiating-urate-loweringurate-lowering-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gout-initiating-urate-loweringurate-lowering-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100621361","phase-4-hla-b5801-guided-therapy-for-gout-effectiveness-safety-and-cost-effectiveness-100621361",false,"NCT07369622","HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness","A Prospective Interventional Study Comparing Genotype-Guided Therapy Versus Usual Care to Prevent Severe Cutaneous Adverse Reactions Associated With Allopurinol and Carbamazepine in Vietnam","HLA-SCREEN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n\nDiagnosis of gout according to the 2020 ACR\u002FEULAR classification criteria.\n\nIndicated for initiation of urate-lowering therapy (ULT) and allopurinol-naïve (no prior allopurinol exposure).\n\nAble and willing to comply with scheduled follow-up visits (baseline, Months 1, 3, 6, and 12).\n\nProvides written informed consent for participation.\n\nFor the genotyping arms: provides consent for blood sampling and HLA-B\\*58:01 genotyping.\n\nExclusion Criteria:\n\n* Prior use of allopurinol or history of hypersensitivity reaction to allopurinol.\n\nKnown hypersensitivity to febuxostat (for participants who would receive febuxostat).\n\nCurrent or recent severe skin reaction (suspected\u002Fconfirmed SCAR) from any cause.\n\nEnd-stage kidney disease requiring dialysis or kidney transplantation.\n\nSevere hepatic impairment or active severe liver disease (e.g., AST\u002FALT \\>3× ULN at baseline).\n\nSevere uncontrolled medical conditions that, in the investigator's judgment, could interfere with treatment or follow-up (e.g., decompensated heart failure, active malignancy requiring intensive treatment).\n\nUse of systemic immunosuppressive therapy (e.g., high-dose corticosteroids, biologics, chemotherapy) at enrollment.\n\nPregnancy or breastfeeding.\n\nParticipation in another interventional clinical study that could affect the outcomes of this study.\n\nInability to provide informed consent or inability to adhere to study procedures.",true,"ALL",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome\u002Ftoxic epidermal necrolysis (SJS\u002FTEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that can occur after starting allopurinol for gout. The HLA-B58:01 allele is a strong genetic risk factor for allopurinol-associated SCARs in Asian populations. This study evaluates the feasibility and clinical value of HLA-B58:01 screening before first-time allopurinol use in Vietnamese adults with gout.\n\nAdults (≥18 years) diagnosed with gout (ACR\u002FEULAR 2020 criteria) and initiating urate-lowering therapy will be enrolled at Hai Phong International General Hospital (January 2025-June 2027). Participants who undergo HLA-B58:01 genotyping (PCR-based assay) will be treated according to test results: HLA-B58:01 negative participants receive allopurinol; HLA-B58:01 positive participants receive febuxostat. A comparison group consists of patients treated with febuxostat without HLA testing. Participants will be followed for 12 months with assessments at baseline, 1, 3, 6, and 12 months to monitor serum uric acid, gout flares, and safety outcomes (SCARs and other adverse events, including liver and kidney function). The study also includes an economic evaluation to estimate the cost-effectiveness of HLA-B58:01 screening for preventing SCARs and optimizing gout treatment.",[27,28,29],"Gout Initiating Urate-loweringUrate-lowering Therapy","Gout Arthritis","Gout and Hyperuricemia",[31,32,33,34,35,36,37,38,39,40],"HLA-B*58:01","HLA genotyping","Pharmacogenomics","Allopurinol","febuxostat","Pharmacogenetic screening","Severe cutaneous adverse reactions (SCARs)","Stevens-Johnson syndrome (SJS)","Toxic epidermal necrolysis (TEN)","Cost-effectiveness analysis","NOT_YET_RECRUITING","2026-01-18",{"date":44,"type":45},"2026-01-27","ACTUAL",{"date":47,"type":21},"2026-01-20",{"date":49,"type":21},"2028-12-30",{"name":51,"class":52},"Haiphong University of Medicine and Pharmacy","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100590724","nurse-led-telehealth-for-gout-100590724","NCT06971146","Nurse-Led Telehealth for Gout","Health Literacy-Based, Nurse-Led Telehealth Support for Gout Self-Management: the Danish Randomized GOUTCONNECT Trial","GoutConnect","Inclusion Criteria:\n\n* ≥18 years old\n* Fulfills ACR\u002FEULAR 2015 Gout Classification Criteria\n* Estimated Glomerular Filtration Rate (e-GFR) \\>30 ml\u002Fmin\n* Prescribed Allopurinol or Adenuric, and achieved two consecutive serum urate levels of two consecutive serum urate levels of ≤0.30 mmol\u002Fl for patients with tophi and ≤0.36 mmol\u002FL for patients without tophi\n* Have sufficient Danish reading and writing skills to understand information and complete questionnaires.\n\nExclusion Criteria:\n\n• Cognitively impaired, unable to understand or provide informed consent.","18 Years",{"count":63,"type":21},200,[65],"NA","The aim of this clinical trial is to evaluate whether nurse-led telehealth support helps individuals with gout better manage their condition and adhere to urate-lowering medication after discharge from a rheumatology clinic.\n\nEligible patients will be recruited from five rheumatology departments in the Central Denmark Region after achieving two consecutive target serum urate levels-below 0.36 mmol\u002FL, or below 0.30 mmol\u002FL for patients with tophi.\n\nParticipants will be adults with gout who meet specific medical criteria, are taking medications such as allopurinol or Adenuric, and are able to read and write Danish.\n\nParticipants will be randomly assigned to one of two groups:\n\n* Intervention group: nurse-led telehealth support.\n* Control group: usual care with follow-up by their general practitioner.\n\nThe primary goal is to support patients in maintaining healthy uric acid levels after 52 weeks.\n\nParticipants in the nurse-led group have the option to choose from four support options:\n\nI1: App-Based Support - an app provides information and reminders. I2: Letter Reminders - messages are sent via digital or postal mail. I3: Text Reminders - SMS messages are sent every three months. I4: Phone Support - nurses call three times a year to check in.",[68,28,27,69,70,71],"Health Literacy","Telehealth","Digital Health","Adherence",[73],"self-managment","RECRUITING","2025-09-17",{"date":77,"type":45},"2025-09-18",{"date":79,"type":21},"2025-10-01",{"date":81,"type":21},"2027-08-01",{"name":83,"class":52},"University of Aarhus",5]